What is Recipharm?
Established in 1995 and headquartered in Stockholm, Sweden, Recipharm operates as a prominent contract development and manufacturing organization (CDMO). The company's core mission involves providing comprehensive support to pharmaceutical and biotech firms, facilitating the journey of therapeutic products from the initial stages of research and development through to full-scale commercial manufacturing. Recipharm's expertise spans a wide array of services, positioning it as a critical partner for companies seeking to navigate the complex landscape of drug production and supply chain management.
How much funding has Recipharm raised?
Recipharm has raised a total of $612.4M across 8 funding rounds:
Share Placement
$20M
Debt
$101.3M
Stock Offering
$87M
Debt
$160.2M
Stock Offering
$29.5M
Debt
$106.8M
Stock Offering
$54.2M
Stock Offering
$53.4M
Share Placement (2011): $20M with participation from Nordea Funds
Debt (2012): $101.3M led by Swedbank AB
Stock Issuance/Offering (2014): $87M supported by Undisclosed
Debt (2014): $160.2M featuring Swedbank, DNB, and Handelsbanken
Stock Issuance/Offering (2016): $29.5M backed by Undisclosed
Debt (2016): $106.8M with participation from Undisclosed
Stock Issuance/Offering (2018): $54.2M led by Undisclosed
Stock Issuance/Offering (2020): $53.4M supported by Gladiator, Lansforsakringar, and Polar Capital
Key Investors in Recipharm
Gladiator
Gladiator is an investor participating in the funding round, likely focused on strategic growth opportunities within the pharmaceutical manufacturing sector.
Lansforsakringar
Lansforsakringar is an investor contributing to Recipharm's financing, potentially representing a Swedish financial institution with a broad investment mandate.
Polar Capital
Polar Capital is an investor in Recipharm, suggesting a focus on technology and growth companies, possibly within the healthcare or life sciences industries.
What's next for Recipharm?
With a history of significant capital infusions, including its latest major strategic investment, Recipharm is well-positioned for continued growth and innovation. The company's enterprise-level funding context suggests a focus on scaling operations, expanding its service portfolio, and potentially pursuing strategic acquisitions to enhance its market reach and technological capabilities. Future developments are likely to center on strengthening its position as a leading global CDMO, adapting to evolving regulatory environments, and meeting the increasing demand for specialized pharmaceutical manufacturing solutions.
See full Recipharm company page
